Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) FCF Margin (2016 - 2025)

Historic FCF Margin for Aytu Biopharma (AYTU) over the last 17 years, with Q4 2025 value amounting to 24.12%.

  • Aytu Biopharma's FCF Margin rose 62500.0% to 24.12% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.11%, marking a year-over-year decrease of 14400.0%. This contributed to the annual value of 3.26% for FY2025, which is 6300.0% down from last year.
  • As of Q4 2025, Aytu Biopharma's FCF Margin stood at 24.12%, which was up 62500.0% from 4.45% recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's FCF Margin ranged from a high of 146.11% in Q1 2021 and a low of 38.11% during Q4 2021
  • Moreover, its 5-year median value for FCF Margin was 6.05% (2024), whereas its average is 1.62%.
  • As far as peak fluctuations go, Aytu Biopharma's FCF Margin tumbled by -1837800bps in 2022, and later skyrocketed by 563400bps in 2023.
  • Aytu Biopharma's FCF Margin (Quarter) stood at 38.11% in 2021, then skyrocketed by 76bps to 9.33% in 2022, then skyrocketed by 92bps to 0.72% in 2023, then surged by 2582bps to 17.87% in 2024, then skyrocketed by 35bps to 24.12% in 2025.
  • Its FCF Margin stands at 24.12% for Q4 2025, versus 4.45% for Q3 2025 and 18.41% for Q2 2025.